STOCK TITAN
  1. Home
  2. News
  3. ACLX

Arcellx Inc - ACLX STOCK NEWS

Welcome to our dedicated news page for Arcellx (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on Arcellx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcellx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcellx's position in the market.

News
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Arcellx, Inc. (ACLX) will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The company focuses on developing innovative immunotherapies for cancer and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
-
News
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Rhea-AI Summary
Arcellx, Inc. (ACLX) to participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. The company focuses on developing innovative immunotherapies for cancer and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences
-
News
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Arcellx, Inc. (ACLX) will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference. The discussion will focus on the development of innovative immunotherapies for cancer and other diseases. A live webcast will be available on Arcellx's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
News
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
Rhea-AI Summary
Arcellx, Inc. reported significant business and financial achievements for Q4 and full year 2023, including an expanded partnership with Kite Pharma, robust long-term responses from anito-cel Phase 1 trial, and ending the quarter with $729.2M cash. The company's continued progress in cell therapy development and strategic collaborations position it for future growth and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
earnings
-
News
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) announces promising clinical data from its Phase 1 expansion study of anitocabtagene autoleucel (anito-cel) for patients with relapsed or refractory multiple myeloma. The study shows deep and durable responses with a 100% overall response rate, 29 out of 38 patients achieved a complete response, and 35 out of 38 patients achieved a very good partial response or higher. The estimated median progression free survival for the study population was 28 months at the time of the data cut with 26.5 months of median follow-up. Anito-cel dosed at 115 million CAR+ T cells continues to be well-tolerated with manageable adverse events and no cases of grade 3 or greater CRS and only one case of grade 3 ICANS event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Kite and Arcellx Announce Expansion in Strategic Partnership
Rhea-AI Summary
Gilead (GILD) & Arcellx (ACLX) expand collaboration for CART-ddBCMA & ARC-SparX program ACLX-001. Kite exercises option to negotiate license for ARC-SparX program ACLX-001 in multiple myeloma. Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment. The collaboration aims to bring potentially best-in-class cell therapy to patients, expanding opportunities in lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
News
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, with Kite investing $200M at $61.68 per share and an $85 million upfront cash payment. Kite exercised its option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma and expanded the collaboration to include lymphomas. This investment is anticipated to extend Arcellx's cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
-
News
Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) reported positive results from its Phase 1 CART-ddBCMA trial with a median duration of response, progression free survival, and overall survival not reached in patients with a median follow-up of 22 months after infusion. The company will present new patient data from the trial during an oral presentation at the 65th ASH Annual Meeting in December, with a median follow-up of 26.5 months. The financial results for the third quarter ended September 30, 2023, show that Arcellx had cash, cash equivalents, and marketable securities of $482.7 million, and collaboration revenue was $15.0 million. Research and development expenses decreased to $43.8 million, and general and administrative expenses increased to $16.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
earnings
-
News
Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition
Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) will present new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma at the 65th American Society of Hematology (ASH) Annual Meeting. The data shows deep and durable responses in patients with poor prognostic factors, with an overall response rate of 100% and a complete response rate of 76%. The median duration of response, progression-free survival, and overall survival were not reached at the time of the data cut. The presentation will include new data with a median follow-up of 26.5 months. Arcellx will also host a live webcast event to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.55%
Tags
clinical trial
News
Arcellx to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) announced its participation in two upcoming investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit (Virtual) and Stifel 2023 Healthcare Conference (In Person). The discussions will be accessible via webcast on Arcellx's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
Stock ACLX logo
Arcellx Inc

Nasdaq:ACLX

ACLX Rankings

#1605 Ranked by Market Cap
#577 Ranked by Stock Gains
N/A Ranked by Dividends

ACLX Stock Data

2.94B
34.18M
12.8%
90.19%
7.14%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Gaithersburg

About ACLX

Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.